Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status Prescription
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 62332-412; 43598-856; 57664-769; 62332-411; 62756-569; 0078-0469; 70771-1411; 66039-871; 69097-550; 70771-1471; 72647-371; 62512-0078; 68462-494; 69539-021; 31722-012; 69097-391; 57664-770; 58032-2017; 69539-200; 63278-1070; 72647-372; 46708-324; 69452-159; 62332-410; 53104-7713; 72606-014; 11722-040; 69097-570; 43598-851; 62332-324; 67877-549; 69539-022; 66022-0301; 0591-3853; 45963-456; 14501-0049; 46708-410; 62332-325; 46708-879; 72606-013; 62756-570; 69238-1486; 43598-854; 65085-0063; 62332-326; 69238-1704; 70710-1011; 59285-010; 46708-326; 70710-1012; 59651-419; 16714-995; 69539-199; 72205-076; 65727-037; 74436-0323; 57664-768; 68462-495; 46708-325; 69452-160; 0078-0713; 65015-738; 16714-993; 69097-393; 69097-560; 0078-0470; 31722-013; 69539-074; 43598-853; 70700-269; 70771-1409; 49706-2103; 70710-1277; 43598-855; 0078-0468; 65372-1164; 16714-994; 43598-852; 45963-455; 46708-412; 0078-0727; 70771-1472; 72647-373; 68462-496; 67877-553; 69238-1703; 45963-454; 69452-161; 0078-0654; 62756-568; 70771-1473; 69539-023; 67877-550; 0078-0720; 70710-1275; 31722-011; 72606-015; 70771-1410; 69539-075; 67877-551; 70710-1013; 67877-554; 72205-075; 0078-0656; 70700-270; 69238-1702; 0078-0655; 46708-411; 69097-392; 69539-073; 69238-1487; 67877-552; 70700-271; 70710-1276; 69238-1488
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Aneurysm24.02.01.0010.002282%Not Available
Anger19.04.02.001--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema10.01.05.009; 23.04.01.001--Not Available
Anorectal disorder07.03.01.0010.005831%Not Available
Anuria20.01.03.0020.017494%Not Available
Anxiety19.06.02.002--
Apathy19.04.04.002--Not Available
Aphasia19.21.01.001; 17.02.03.001--
Aphonia19.19.01.002; 22.02.05.024; 17.02.08.0090.005831%
Aphthous ulcer07.05.06.0020.008747%Not Available
Aplasia08.03.04.003; 03.02.01.0020.005831%Not Available
Aplasia pure red cell10.02.01.003; 01.03.03.0010.026240%Not Available
Aplastic anaemia01.03.03.0020.019775%Not Available
Appendicitis11.01.07.001; 07.19.01.0010.011662%
Arrhythmia02.03.02.0010.032071%Not Available
Arterial thrombosis24.01.01.0020.005831%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Ascites09.01.05.003; 07.07.01.001; 02.05.04.0020.034987%
Aspartate aminotransferase decreased13.03.01.0050.005831%Not Available
Aspartate aminotransferase increased13.03.01.0060.096214%
Asthenia08.01.01.0010.221585%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atrial fibrillation02.03.03.002--
Atrophy08.03.04.0010.011662%Not Available
Azotaemia20.01.01.0010.005831%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 28 Pages